MYUNGIN PHARM Files Corporate Governance Report: Dividend Expansion and Value-Up Plan Established, Continuous Governance Improvement
MYUNGIN PHARM disclosed its corporate governance report as of May 29, 2026, its first regular report since listing on KOSPI in October 2025, demonstrating efforts to enhance management transparency.
Dividends per share have steadily increased over three years (2023: 500 won → 2024: 1,000 won → 2025: 1,500 won), with a 2025 consolidated payout ratio of 26.89%, reinforcing shareholder return policy.
On March 27, 2026, the company voluntarily disclosed a 'Value-Up Plan' aiming to solidify its No.1 market share in CNS and secure growth through improved new drugs and new pipelines.
Transitioned to a professional management system on April 1, 2026 (appointment of co-CEOs), separating ownership and management to advance governance.
All four board committees (Audit, Internal Transaction, Outside Director Nomination, ESG Sustainability) are composed entirely of outside directors, ensuring audit committee independence.
Some governance core indicators remain unfulfilled: AGM notice less than 4 weeks prior, no electronic voting, no formal dividend policy, and an all-male board.
[AI Summary]MYUNGIN PHARM's corporate governance report is a routine disclosure at an early listed stage, showing neutral impact. Dividend expansion and the value-up plan are positive, but improvements in e-voting and dividend policy are needed. Overall, no major positive or negative catalysts for stock price.